Adjunctive everolimus therapy in tuberous sclerosis-associated refractory epilepsy

Diagnosis The patient diagnosed with refractory seizure associated with tuberous sclerosis.

Treatment The patient was treated with everolimus, and he was commenced at a dose of 10 mg daily.

Conclusion This report shows that everolimus treatment for three years of refractory seizures in patients with TSC, can lead to a clinically meaningful reduction in seizure frequency. Compared with other anti-epileptic medications, everolimus demonstrated additional benefits in reducing Subependymal giant cell astrocytoma (SEGA) and renal angiomyolipoma volume. At the time of preparation of this report, the patient continue treatment with daily everolimus without adverse events.